Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pupillometry Guided Remifentanil Administration In Pediatric Anesthesia
NCT02683837 · University Hospital, Geneva · NA · withdrawn · last registry update 2024-04-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Principal investigator left the institution” | – | Registry record, University Hospital, Geneva |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against OPRM1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-04-03Results posted on the registry: Yale University, a drug against OPRM1 (NCT04180020)
- 2025-03-13Results posted on the registry: Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program, Morphine + Methadone (NCT04214834)
- 2025-01-14Results posted on the registry: Montefiore Medical Center, Buprenorphine (NCT03150173)
- 2025-01-09Results posted on the registry: University of Vermont, a drug against OPRM1 (NCT04104022)
- 2024-12-11Phase 3 first posted: Chinese University of Hong Kong, Methadone + Morphine (NCT06728371)
- 2024-10-15Results posted on the registry: National Cancer Institute (NCI), Selinexor + Temozolomide (NCT04216329)
- 2024-10-09Phase 3 first posted: University of California, San Francisco, IM naltrexone (NCT06633900)
- 2024-10-04Phase 3 first posted: Senthil Sadhasivam, Methadone based ERAS + Non-methadone based group (NCT06626503)
- 2024-10-03Phase 3 first posted: Senthil Sadhasivam, Methadone based ERAS + Non-methadone based group (NCT06626035)
- 2024-09-19Phase 3 first posted: Indiana University, Inrathecal Morphine + Intravenous Methadone (NCT06593665)
- 2024-09-19Results posted on the registry: National Cancer Institute (NCI), Cediranib + Sunitinib (NCT01391962)
- 2024-07-10Phase 3 first posted: Yale University, Buprenorphine (NCT06494904)
- 2024-03-18Phase 3 first posted: Rhode Island Hospital, Buprenorphine (NCT06316830)
- 2024-03-12Phase 3 first posted: Friends Research Institute, Inc., extended-release buprenorphine (XR-B) (NCT06306443)
- 2023-12-12Results posted on the registry: Ochsner Health System, a drug against OPRM1 (NCT03889418)
- 2023-10-18Phase 3 first posted: University of Maryland, Baltimore, Naloxone Nasal Spray (NCT06089707)
- 2023-10-02Results posted on the registry: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, ketamine infusion + Methadone PCA (NCT01594047)
- 2023-09-13Phase 3 first posted: Rutgers, The State University of New Jersey, a drug against OPRM1 (NCT06033599)
- 2023-09-05Phase 3 first posted: Yih-Ing Hser, Injectable extended-release buprenorphine + Sublingual buprenorphine-naloxone (NCT06023459)
- 2023-06-22Phase 3 first posted: Chinese University of Hong Kong, Methadone + Morphine (NCT05913284)
- 2023-04-24Phase 3 first posted: Yale University, Naltrexone Pill + Naltrexone Injection (NCT05827159)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision